Cargando…
IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
Diagnostic evaluation of specific antibodies against the SARS-CoV-2 virus is mainly based on spike (S) and nucleocapsid (N) proteins. Despite the critical functions in virus infection and contribution to the pattern of immunodominance in COVID-19, exploitation of the most abundant membrane (M) prote...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125631/ https://www.ncbi.nlm.nih.gov/pubmed/34066920 http://dx.doi.org/10.3390/ijms22094951 |
_version_ | 1783693560925650944 |
---|---|
author | Lopandić, Zorana Protić-Rosić, Isidora Todorović, Aleksandra Glamočlija, Sofija Gnjatović, Marija Ćujic, Danica Gavrović-Jankulović, Marija |
author_facet | Lopandić, Zorana Protić-Rosić, Isidora Todorović, Aleksandra Glamočlija, Sofija Gnjatović, Marija Ćujic, Danica Gavrović-Jankulović, Marija |
author_sort | Lopandić, Zorana |
collection | PubMed |
description | Diagnostic evaluation of specific antibodies against the SARS-CoV-2 virus is mainly based on spike (S) and nucleocapsid (N) proteins. Despite the critical functions in virus infection and contribution to the pattern of immunodominance in COVID-19, exploitation of the most abundant membrane (M) protein in the SARS-CoV-2 serology tests is minimal. This study investigated the recombinant M protein’s immunoreactivity with the sera from COVID-19 convalescents. In silico designed protein was created from the outer N-terminal part (19 aa) and internal C-terminal tail (101–222 aa) of the M protein (YP_009724393.1) and was recombinantly produced and purified. The designed M protein (16,498.74 Da, pI 8.79) revealed both IgM and IgG reactivity with serum samples from COVID-19 convalescents in Western blot. In ELISA, more than 93% (28/30) of COVID-19 sera were positive for IgM detection, and more than 96% (29/30) were positive for specific IgG detection to M protein. Based on the capacity to provoke an immune response and its strong antigenic properties, as shown here, and the fact that it is also involved in the virion entry into host cells, the M protein of the SARS-CoV-2 virus as a good antigen has the potential in diagnostic purposes and vaccine design. |
format | Online Article Text |
id | pubmed-8125631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81256312021-05-17 IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein Lopandić, Zorana Protić-Rosić, Isidora Todorović, Aleksandra Glamočlija, Sofija Gnjatović, Marija Ćujic, Danica Gavrović-Jankulović, Marija Int J Mol Sci Article Diagnostic evaluation of specific antibodies against the SARS-CoV-2 virus is mainly based on spike (S) and nucleocapsid (N) proteins. Despite the critical functions in virus infection and contribution to the pattern of immunodominance in COVID-19, exploitation of the most abundant membrane (M) protein in the SARS-CoV-2 serology tests is minimal. This study investigated the recombinant M protein’s immunoreactivity with the sera from COVID-19 convalescents. In silico designed protein was created from the outer N-terminal part (19 aa) and internal C-terminal tail (101–222 aa) of the M protein (YP_009724393.1) and was recombinantly produced and purified. The designed M protein (16,498.74 Da, pI 8.79) revealed both IgM and IgG reactivity with serum samples from COVID-19 convalescents in Western blot. In ELISA, more than 93% (28/30) of COVID-19 sera were positive for IgM detection, and more than 96% (29/30) were positive for specific IgG detection to M protein. Based on the capacity to provoke an immune response and its strong antigenic properties, as shown here, and the fact that it is also involved in the virion entry into host cells, the M protein of the SARS-CoV-2 virus as a good antigen has the potential in diagnostic purposes and vaccine design. MDPI 2021-05-07 /pmc/articles/PMC8125631/ /pubmed/34066920 http://dx.doi.org/10.3390/ijms22094951 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lopandić, Zorana Protić-Rosić, Isidora Todorović, Aleksandra Glamočlija, Sofija Gnjatović, Marija Ćujic, Danica Gavrović-Jankulović, Marija IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein |
title | IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein |
title_full | IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein |
title_fullStr | IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein |
title_full_unstemmed | IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein |
title_short | IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein |
title_sort | igm and igg immunoreactivity of sars-cov-2 recombinant m protein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125631/ https://www.ncbi.nlm.nih.gov/pubmed/34066920 http://dx.doi.org/10.3390/ijms22094951 |
work_keys_str_mv | AT lopandiczorana igmandiggimmunoreactivityofsarscov2recombinantmprotein AT proticrosicisidora igmandiggimmunoreactivityofsarscov2recombinantmprotein AT todorovicaleksandra igmandiggimmunoreactivityofsarscov2recombinantmprotein AT glamoclijasofija igmandiggimmunoreactivityofsarscov2recombinantmprotein AT gnjatovicmarija igmandiggimmunoreactivityofsarscov2recombinantmprotein AT cujicdanica igmandiggimmunoreactivityofsarscov2recombinantmprotein AT gavrovicjankulovicmarija igmandiggimmunoreactivityofsarscov2recombinantmprotein |